-
Eli Lilly To Present Data From Key Molecules That Make Up Its Clinical Oncology Pipeline At ASCO 2013
5/14/2013
|
|
|
-
Eli Lilly: CEO John Lechleiter Underwent Scheduled Surgery For Dilated Aorta On May 13
5/14/2013
|
|
|
|
|
-
Eli Lilly Says Enzastaurin Phase III Study Did Not Meet Primary Endpoint In Diffuse Large B-Cell Lymphoma
5/10/2013
|
|
|
-
Lilly CEO John Lechleiter To Undergo Scheduled Surgery For Dilated Aorta On May 13
5/6/2013
|
-
Eli Lilly And Co. (LLY) Declares $ 0.49 Dividend for Q2 13, Record Date 5/16/2013
5/6/2013
|
-
Barclays Capital Is Increasing Eli Lilly And Co. (LLY) FY13 Estimate To 3.96 From 3.93
4/25/2013
|